Biocon Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Biocon Limited signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon has signed an out-licensing deal with Ajanta Pharma, allowing Ajanta to market Biocon's Semaglutide across 26 countries. Semaglutide is the generic equivalent of blockbuster GLP-1 drugs Ozempic and Wegovy, widely used for type-2 diabetes and weight management. Through this agreement, Biocon monetises its Semaglutide portfolio by leveraging Ajanta's established distribution and marketing network in these markets rather than building its own. Biocon is expected to receive upfront payments, milestone-based payments, and royalties on sales. The 26-country footprint helps Biocon tap into the rapidly growing global demand for affordable GLP-1 therapies, particularly in emerging markets.
Positive for shareholders — the deal expands Biocon's international reach for a high-demand product without significant capital outlay, and adds a new revenue stream through royalties and milestone payments.